ERBB2 and non-small cell lung carcinoma: Immunoprecipitation experiments revealed that the binding of HER3 to EGFR and HER2 was enhanced in DT cells (Fig. 1d and Supplementary Fig. 1d), suggesting that DT cell survival was maintained by HER3 signaling in some ALK-rearranged NSCLC cells, presumably via interactions with EGFR or HER2.